July 8, 2010
Recent research by Ron Schultz, professor and chair of the Department of Pathobiological Sciences at the University of Wisconsin–Madison School of Veterinary Medicine, has shown the newly approved Canine Influenza Virus (CIV) vaccine to be effective not only in reducing length, severity and spread of the virus, but also in protecting against secondary infections.